Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$5.11 +5.1%	$8.40	$3.80 ▼ $47.80	$8.10M	-1.27	62,381 shs	99,836 shs
ARTL Artelo Biosciences	$10.02 -0.7%	$11.29	$4.92 ▼ $28.60	$7.06M	1.36	144,431 shs	18,270 shs
GRTX Galera Therapeutics	$0.02 +2.3%	$0.03	$0.02 ▼ $0.08	$1.70M	1.91	91,367 shs	7,670 shs
INAB IN8bio	$2.37 -1.3%	$2.27	$1.98 ▼ $21.21	$10.76M	0.01	111,097 shs	109,621 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	0.00%	+14.32%	-43.10%	-33.98%	-86.55%
ARTL Artelo Biosciences	0.00%	+20.00%	-36.06%	+81.52%	+26.52%
GRTX Galera Therapeutics	0.00%	-2.17%	-15.41%	-5.86%	-68.31%
INAB IN8bio	0.00%	+2.60%	+7.73%	-38.62%	-86.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	3.0302 of 5 stars	3.5	5.0	0.0	0.0	2.7	1.7	0.0
ARTL Artelo Biosciences	2.8855 of 5 stars	3.8	5.0	0.0	0.0	1.7	0.0	0.6
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	4.0508 of 5 stars	3.5	5.0	0.0	0.0	4.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$31.00	506.65% Upside
ARTL Artelo Biosciences	3.60	Strong Buy	$24.00	139.52% Upside
GRTX Galera Therapeutics	0.00	N/A	N/A	N/A
INAB IN8bio	3.00	Buy	$180.00	7,494.94% Upside

Current Analyst Ratings Breakdown

Latest GRTX, ACXP, INAB, and ARTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$31.00
8/4/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
7/8/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00
6/11/2025	ARTL Artelo Biosciences	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/6/2025	ARTL Artelo Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.25 per share	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	($2.00) per share	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	($2.41) per share	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$10.69	N/A	N/A	N/A	N/A	-436.83%	-192.25%	N/A
ARTL Artelo Biosciences	-$9.83M	-$19.05	N/A	N/A	N/A	N/A	-497.68%	-213.76%	N/A
GRTX Galera Therapeutics	-$59.08M	-$0.19	N/A	∞	N/A	N/A	N/A	-99.34%	N/A
INAB IN8bio	-$30.44M	-$9.11	N/A	N/A	N/A	N/A	-184.97%	-126.75%	N/A

Latest GRTX, ACXP, INAB, and ARTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ARTL Artelo Biosciences	-$0.13	-$5.61	-$5.48	-$5.61	N/A	N/A
8/11/2025	Q2 2025	ACXP Acurx Pharmaceuticals	-$2.00	-$1.89	+$0.11	-$1.89	N/A	N/A
8/7/2025	Q2 2025	INAB IN8bio	-$1.50	-$1.24	+$0.26	-$1.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	2.38	1.93
ARTL Artelo Biosciences	N/A	0.39	0.49
GRTX Galera Therapeutics	N/A	9.74	9.74
INAB IN8bio	0.01	7.03	7.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
ARTL Artelo Biosciences	0.87%
GRTX Galera Therapeutics	50.77%
INAB IN8bio	92.05%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	20.30%
ARTL Artelo Biosciences	5.80%
GRTX Galera Therapeutics	12.90%
INAB IN8bio	15.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	1.59 million	1.26 million	Optionable
ARTL Artelo Biosciences	5	704,000	663,000	Not Optionable
GRTX Galera Therapeutics	30	75.46 million	47.38 million	Optionable
INAB IN8bio	20	4.54 million	3.84 million	Not Optionable

GRTX, ACXP, INAB, and ARTL Headlines

Recent News About These Companies

IN8bio (NASDAQ:INAB) Rating Increased to Hold at Wall Street Zen

August 9, 2025 | americanbankingnews.com

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 7, 2025 | globenewswire.com

IN8bio (INAB) Projected to Post Earnings on Thursday

August 7, 2025 | americanbankingnews.com

IN8bio, Inc. (INAB) stock price, news, quote & history – Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

IN8bio Regains Nasdaq Compliance with Bid Price Rule

June 30, 2025 | tipranks.com

IN8bio, Inc: IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

June 9, 2025 | finanznachrichten.de

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

June 9, 2025 | globenewswire.com

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

June 2, 2025 | globenewswire.com

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 14, 2025 | globenewswire.com

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 12, 2025 | globenewswire.com

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025 | globenewswire.com

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

April 29, 2025 | globenewswire.com

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

April 28, 2025 | globenewswire.com

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (?d) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

March 31, 2025 | tmcnet.com

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

March 31, 2025 | globenewswire.com

IN8bio to Participate in Immuno-Oncology 360° Conference 2025, Highlighting Advances in Gamma-Delta T Cell Therapies

March 18, 2025 | quiverquant.comQ

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

March 18, 2025 | globenewswire.com

INAB: Introducing INB-600, A γδ T Cell Engager Platform

March 17, 2025 | msn.com

IN8bio Reports Strong Clinical Progress and Expands Pipeline with Innovative Gamma-Delta T Cell Therapies

March 15, 2025 | nasdaq.com

IN8BIO Earnings Results: $INAB Reports Quarterly Earnings

March 15, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRTX, ACXP, INAB, and ARTL Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$5.11 +0.25 (+5.14%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$5.04 -0.08 (-1.47%)

As of 08/15/2025 07:59 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Artelo Biosciences NASDAQ:ARTL

$10.02 -0.07 (-0.69%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$9.98 -0.04 (-0.40%)

As of 08/15/2025 07:49 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Galera Therapeutics NASDAQ:GRTX

$0.02 +0.00 (+2.27%)

As of 08/15/2025 11:54 AM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

IN8bio NASDAQ:INAB

$2.37 -0.03 (-1.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.32 -0.06 (-2.32%)

As of 08/15/2025 07:55 PM Eastern

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time